We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for nirogacestat hydrobromide (Merck Healthcare Pty Ltd)
Active ingredients
nirogacestat hydrobromide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablet
Indication
For the treatment of desmoid tumours
Therapeutic area
Oncology